CLINICAL DEVELOPMENT-THE BOTTLENECK OF INNOVATIVE DRUG DEVELOPMENT IN CHINA
CLINICAL DEVELOPMENT IS EXTREMELY DIFFICULT AND DEMANDINGClinical development is the only method to test a drug's
safety and effectiveness in humans, and directly determines the success or failure of an innovative drug.
Compared to western countries, China is a late starter in clinical development, and has limited experience in designing clinical studies. Also, the number of clinical studies (especially PhI) are relatively low and the quality varies greatly.
INDEPENDENTLY DEVELOPED, CLINICALLY DRIVEN
—— BUILD A LEADING MODEL FOR INNOVATIVE DRUG DEVELOPMENT
Translational Medicine
Research Center
Build a first-class domestic platform for
research, collaboration, and talent development
Boost translational medicine, enrich R&D pipeline, and enhance clinical studies
Global Strategic Product
Acquisitions and Co-Developments
With a focus on China's high-incidence cancers and the needs of Chinese patients,
in-license attractive assets globally or custom design and develop through preclinical CROs
World-Class
“Clinical Development Engine”
Global standards, China focused
Leverage the clinical team's industry-leading capabilities to accelerate clinical development & drug registration, while adhering to international standards and quality
Commercialize Products in China and Globally
Build internal commercial infrastructure in China
Co-develop and co-market outside China
CSTONE HAS THE WEAPON TO BREAK THE BOTTLENECK OF CLINICAL DEVELOPMENT
A HIGH-QUALITY, HIGH-EFFICIENCY, AND LOW-COST MODEL FOR INNOVATIVE DRUG DEVELOPMENT
High-Quality, Low-Cost
To ensure quality, CStone keeps the most critical clinical development functions in-house; while collaborating with the best CROs to lower operating costs and conduct multiple clinical trials simultaneously
High-Efficiency
Leverage an innovative model to shorten the timeline for
clinical development